Chaney Capital Management, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Chaney Capital Management, Inc.
- $224 Billion
- Q1 2025
A detailed history of Chaney Capital Management, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Chaney Capital Management, Inc. holds 11,167 shares of LXRX stock, worth $7,816. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,167Holding current value
$7,816% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
134Shares Held
196MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$95.3 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$6.92 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$6.69 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$5.75 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$2.58 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $132M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...